Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Abstract Text:

Daisuke Ennishi,Yasuhito Terui,Masahiro Yokoyama,Yuko Mishima,Shunji Takahashi,Kengo Takeuchi,Hiroaki Okamoto,Mitsune Tanimoto,Kiyohiko Hatake,Daisuke Ennishi,Yasuhito Terui,Masahiro Yokoyama,Yuko Mishima,Shunji Takahashi,Kengo Takeuchi,Hiroaki Okamoto,Mitsune Tanimoto,Kiyohiko Hatake,

Several studies have shown that the frequency of hepatitis C virus (HCV) infection is high in patients with B-cell non-Hodgkin's lymphoma (NHL). In these studies, liver dysfunction during chemotherapy has been demonstrated, but changes in HCV ribonucleic acid (RNA) levels during chemotherapy have not been well documented. In this study, we monitored serum HCV RNA levels and liver function in five HCV-infected patients with B-cell NHL undergoing treatment with rituximab-combination chemotherapy. Increased HCV RNA levels during or after the chemotherapy were observed in all five patients, and a significant increase in transaminases was seen in one case. In this case, serum HCV RNA level dramatically decreased at the time of the increase of transaminases, and this suggested that the cause of liver damage was an immune reaction against hepatocytes with HCV and not any anticancer drug induced liver toxicity. Monitoring of serum HCV RNA levels and transaminases may be helpful to understand the cause of liver dysfunction in patients receiving chemotherapy. However, increases of HCV viral load were not associated with the occurrence of liver dysfunction in this study. Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients. Am. J. Hematol., 2008. (c) 2007 Wiley-Liss, Inc.

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Publishing Authors By Initials

D Ennishi,Y Terui,M Yokoyama,Y Mishima,S Takahashi,K Takeuchi,H Okamoto,M Tanimoto,K Hatake,D Ennishi,Y Terui,M Yokoyama,Y Mishima,S Takahashi,K Takeuchi,H Okamoto,M Tanimoto,K Hatake,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of hematology

VOLUME: 83

Page Numbers: 59-62

Journal Abbreviation: Am. J. Hematol.

ISSN: 0361-8609

DAY: 21

MONTH: Jan

YEAR: 2008

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7610369

Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.

AFFILIATION: Department of Medical Oncology and Hematology, Cancer Institute Hospital, Tokyo, Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Hematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Monitoring serum hepatitis C virus HCV RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy Related Publications

• Differential Regulation of Eotaxin-1/CCL11 and Eotaxin-3/CCL26 Production by the TNF-alpha and IL-4 Stimulated Human Lung Fibroblast.
• Does rituximab really induce hepatitis C virus reactivation?
• Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
• Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience.
• Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
• Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
• [A Feasibility Study of Oxaliplatin (L-OHP) in Combination with Infusional 5-FU/l-LV (FOLFOX4 Regimen) for Advanced Colorectal Cancer.]
• [Effect of ethanol on anandamide-induced sensory nerve dependent vasorelaxation (the second report)]
• [Retrospective Analysis of FOLFOX4 Neurotoxicity for Recovery from Advanced Colorectal Cancer.]
• [Safety and Efficacy Analysis of FOLFOX4 Regimen in Elderly Compared to Younger Colorectal Cancer Patients.]